SUZHOU, China – It is a tradition at the annual ChinaBio Partnering Conference that Greg Scott, event founder and organizer, kicks things off with a slideshow to walk participants – biotech and med-tech entrepreneurs, venture capital investors and big pharma – through an impressive China money story. The numbers can surprise even Scott, who has been bearing witness and contributing to the industry's growth for the last decade.

SHANGHAI – Denovo Biopharma LLC, a cross-border biotech with offices in San Diego and Shanghai, has dosed the first patient in a phase III trial of DB-102 (enzastaurin) to treat diffuse large B-cell lymphoma (DLBCL). DB-102 is a serine/threonine kinase inhibitor of the PKC beta and AKT pathways.

SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly and Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities.

SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly & Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities.

SHANGHAI – This year's China Healthcare Investment Conference (CHIC) event, where investors and entrepreneurs gathered between the mirrored walls of the Ritz-Carlton, was especially supercharged, thanks to the recent decision by the Hong Kong Stock Exchange to open its doors to pre-revenue biotech companies, a move that has the potential to usher in a new era of wealth and opportunity for many of the attendees. 

SHANGHAI – This year's China Healthcare Investment Conference (CHIC) event, where investors and entrepreneurs gathered between the mirrored walls of the Ritz-Carlton, was especially supercharged, thanks to the recent decision by the Hong Kong Stock Exchange to open its doors to pre-revenue biotech companies, a move that has the potential to usher in a new era of wealth and opportunity for many of the attendees. 

SHANGHAI - XW Laboratories Inc.'s lead candidate, a small-molecule drug for narcolepsy, has begun dosing in healthy patients in Australia. Based in Wuhan and Taipei, XW Labs decided to head to Australia for phase I for a variety of reasons, even though moving to first-in-human trials in China has become more viable after CFDA reforms.

SHANGHAI - XW Laboratories Inc.'s lead candidate, a small-molecule drug for narcolepsy, has begun dosing in healthy patients in Australia. Based in Wuhan and Taipei, XW Labs decided to head to Australia for phase I for a variety of reasons, even though moving to first-in-human trials in China has become more viable after CFDA reforms.

SHANGHAI – Two-year-old Engine Biosciences Pte Ltd., a startup with an artificial intelligence (AI) platform approach to drug discovery, recently received a $10 million endorsement from Chinese and U.S. investors. Engine is one of a growing number of AI-first, data-driven biotechs that are plying the latest advances in machine learning to the complex task of understanding human biology to find new medicines.